These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20359271)

  • 21. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
    Malaguarnera M; Gargante MP; Cristaldi E; Colonna V; Messano M; Koverech A; Neri S; Vacante M; Cammalleri L; Motta M
    Arch Gerontol Geriatr; 2008; 46(2):181-90. PubMed ID: 17658628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.
    Malaguarnera M; Vacante M; Motta M; Giordano M; Malaguarnera G; Bella R; Nunnari G; Rampello L; Pennisi G
    Metab Brain Dis; 2011 Dec; 26(4):281-9. PubMed ID: 21870121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine.
    Jiang Q; Jiang G; Shi KQ; Cai H; Wang YX; Zheng MH
    Ann Hepatol; 2013; 12(5):803-9. PubMed ID: 24018499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galantamine introduced in Europe.
    Am J Alzheimers Dis Other Demen; 2001; 16(1):8. PubMed ID: 11416951
    [No Abstract]   [Full Text] [Related]  

  • 25. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.
    Suchy J; Chan A; Shea TB
    Nutr Res; 2009 Jan; 29(1):70-4. PubMed ID: 19185780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy in Alzheimer disease].
    Kovács T
    Orv Hetil; 2004 Apr; 145(17):925-8. PubMed ID: 15170971
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug-related neuropathy: low acetylcarnitine levels found.
    James JS
    AIDS Treat News; 1997 Feb; (No 265):6-7. PubMed ID: 11364244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U
    Int J Clin Pharmacol Res; 1990; 10(1-2):75-9. PubMed ID: 2201659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.
    Sima AA
    CNS Drugs; 2007; 21 Suppl 1():13-23; discussion 45-6. PubMed ID: 17696589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the treatment of Alzheimer's disease.
    Schneider LS
    Aging (Milano); 1998 Apr; 10(2):156-7. PubMed ID: 9666210
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy.
    Siciliano M; Annicchiarico BE; Lucchese F; Bombardieri G
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):76-80. PubMed ID: 16445703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals.
    Di Giulio AM; Gorio A; Bertelli A; Mantegazza P; Ferraris L; Ramacci MT
    Int J Clin Pharmacol Res; 1992; 12(5-6):243-6. PubMed ID: 1284499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetyl-L-carnitine in hepatic encephalopathy.
    Malaguarnera M
    Metab Brain Dis; 2013 Jun; 28(2):193-9. PubMed ID: 23389620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
    Malaguarnera M; Vacante M; Giordano M; Pennisi G; Bella R; Rampello L; Malaguarnera M; Li Volti G; Galvano F
    Am J Clin Nutr; 2011 Apr; 93(4):799-808. PubMed ID: 21310833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.
    Sergi G; Pizzato S; Piovesan F; Trevisan C; Veronese N; Manzato E
    Aging Clin Exp Res; 2018 Feb; 30(2):133-138. PubMed ID: 28534301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Therapies in Hepatic Encephalopathy.
    Alimirah M; Sadiq O; Gordon SC
    Clin Liver Dis; 2020 May; 24(2):303-315. PubMed ID: 32245535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome.
    Vermeulen RC; Scholte HR
    Psychosom Med; 2004; 66(2):276-82. PubMed ID: 15039515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats.
    Yin YY; Liu H; Cong XB; Liu Z; Wang Q; Wang JZ; Zhu LQ
    J Alzheimers Dis; 2010; 19(2):735-46. PubMed ID: 20110616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain.
    Onofrj M; Fulgente T; Melchionda D; Marchionni A; Tomasello F; Salpietro FM; Alafaci C; De Sanctis E; Pennisi G; Bella R
    Int J Clin Pharmacol Res; 1995; 15(1):9-15. PubMed ID: 7490173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aging eye and the role of L-carnitine and its derivatives.
    Pescosolido N; Imperatrice B; Karavitis P
    Drugs R D; 2008; 9 Suppl 1():3-14. PubMed ID: 19105587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.